Phase 2B Study
The planned global multicenter, randomized, double blind, placebo controlled, parallel group study will evaluate the benefit of dutogliptin in combination with G-CSF as an adjunct treatment for patients with acute myocardial infarction.
Status of Study
Not yet active; projected to start in Q2.2017.
Study Design
The double-blind, randomized, placebo-controlled study (Phase 2B) will evaluate both safety and efficacy of dutogliptin in combination with G-CSF as an adjunct treatment for patients with acute myocardial infarction.
Patients being considered for participation in this study are those who have had a large myocardial infarction due to coronary artery atherosclerotic disease within the past 72 hours. After completion of screening procedures, patients will be randomized to receive either dutogliptin in combination with G-CSF or placebo.
Patient Population
Patients who have had a myocardial infarction due to coronary artery disease within the past 72 hours and having less than normal heart function as evidenced by left ventricular ejection fraction (LVEF) of left ventricular mass.